文献速递核素与放射性配体治疗肿瘤 PET/CT

定量放射性栓塞吸收剂量对健康肝功能的影响:[99mTc]TcMebrofenin研究

Quantifying the effects of absorbed dose from radioembolisation on healthy liver function with [99mTc]TcMebrofenin.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-20

本研究纳入35例接受放射性栓塞(RE)治疗肝病的患者,于基线和治疗后8周行[99mTc]TcMebrofenin肝胆闪烁显像(HBS),并与治疗后90Y PET/CT衍生的健康肝吸收剂量指标比较。结果发现基线整体肝摄取率(负相关)和D70均与整体肝摄取率变化呈显著线性相关,D70与胆红素和GGT变化呈线性相关。作者认为基线HBS不应单独用于排除RE候选患者,D70可能是最合适的剂量指标,大于15 Gy提示整体肝功能可能下降。

要点

  • 基线整体肝摄取率与D70均与整体肝摄取率变化呈显著线性相关,基线HBS不应单独用于排除RE候选患者。
  • D70与胆红素和GGT变化呈线性相关,D70大于15 Gy提示整体肝功能可能下降。
  • 接受肺叶RE的患者功能负荷发生转移,功能负荷增加区域的平均剂量为9 Gy,降低区域为35 Gy,差异显著。

核心结论

  • 基线整体肝摄取率与整体肝摄取率变化呈显著负相关,基线HBS不应单独用于排除考虑RE的患者。
  • 在治疗计划和评估方面,D70可能是最合适的剂量指标,大于15 Gy提示整体肝功能可能下降。
  • 保留肝体积中功能负荷增加的证据提示,有并发症风险的患者可能从肺叶入路治疗中获益。

研究设计与样本

  • 纳入35例接受放射性栓塞治疗肝病的患者,其中9例接受肺叶治疗。
  • 患者于基线和治疗后8周行[99mTc]TcMebrofenin肝胆闪烁显像(HBS)研究。
  • 将整体肝摄取率变化与治疗后90Y PET/CT衍生的健康肝吸收剂量指标(平均剂量、D70、V50)进行比较。
  • 评估接受肺叶RE患者中治疗相关和保留肝体积的功能负荷变化,以及不同剂量范围对应区域体积的变化。
  • 检查基线与治疗后标准肝功能病理试验(胆红素、白蛋白、ALP、AST、ALT和GGT)的变化。

主要发现

  • 基线整体肝摄取率(负相关)和D70均与整体肝摄取率变化呈显著线性相关。
  • 接受肺叶治疗的患者功能负荷发生转移,功能负荷增加的肝体积对应平均剂量为9 Gy,功能负荷降低的肝体积对应平均剂量为35 Gy,两者差异显著。
  • 无基线肝功能试验预测整体肝功能下降;但D70与胆红素和GGT变化呈线性相关。

关键数值与推荐

  • D70大于15 Gy提示整体肝功能可能下降。
  • 功能负荷增加的肝体积对应平均剂量为9 Gy,功能负荷降低的肝体积对应平均剂量为35 Gy,差异显著。

临床怎么用

  • 作者认为基线HBS不应单独用于排除考虑RE的患者。
  • 作者认为在治疗计划和评估方面,D70可能是最合适的剂量指标,大于15 Gy提示整体肝功能可能下降。
  • 作者认为保留肝体积中功能负荷增加的证据提示,有并发症风险的患者可能从肺叶入路治疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To quantify the effects of absorbed radiation dose on healthy liver parenchyma following radioembolisation (RE) using [99mTc]TcMebrofenin to analyse both global and regional liver function. METHODS: Patients having RE to treat hepatic disease underwent a [99mTc]TcMebrofenin hepatobilliary scintigraphy (HBS) study at both baseline and 8 weeks following treatment. Changes in global liver uptake rate were compared with healthy liver absorbed dose measures derived from the post-treatment 90Y PET/CT, including average dose, minimum dose to 70% of the volume (D70) and volume receiving at least 50 Gy (V50). Changes in functional burden associated with treatment and spared liver volumes in patients receiving lobar RE were also assessed, as were changes experienced by regional volumes corresponding to various dose ranges. Standard liver function pathology tests (LFTs) (bilirubin, albumin, ALP, AST, ALT and GGT) were examined for changes between baseline and post-treatment. RESULTS: Thirty-five patients were included in the study, of which, 9 had lobar treatment. A significant linear correlation was found between both baseline global liver uptake rate (negative) and D70 with change in global liver uptake rate. Patients undergoing lobar treatments demonstrated a shift in functional burden, and a significant difference was seen between the mean dose corresponding to liver volumes that increased their functional burden (9 Gy) and those that decreased their functional burden (35 Gy). No baseline LFTs predicted a decrease in global liver function; however, D70 demonstrated a linear correlation with changes in bilirubin and GGT. CONCLUSIONS: Given the significant negative relationship between baseline and change in global liver uptake rate, baseline HBS studies should not be used alone to disqualify patients considered for RE. In terms of treatment planning and evaluation, D70 may be the most appropriate metric of dose, with values greater than 15 Gy indicative of a likely drop in global liver function. The evidence of increasing functional burden in spared liver volumes suggests that patients at risk of complications could benefit from a lobar approach to treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Willowson KP, Schembri GP, Bernard EJ, et al. Quantifying the effects of absorbed dose from radioembolisation on healthy liver function with [99mTc]TcMebrofenin. Eur J Nucl Med Mol Imaging. 2020. PMID: 31956945. doi:10.1007/s00259-020-04686-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。